Market Cap 4.30B
Revenue (ttm) 0.00
Net Income (ttm) -252.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.02
Volume 640,200
Avg Vol 2,269,788
Day's Range N/A - N/A
Shares Out 79.99M
Stochastic %K 60%
Beta -0.29
Analysts Sell
Price Target $67.44

Company Profile

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 487 6488
Website: akerotx.com
Address:
601 Gateway Boulevard, Suite 350, South San Francisco, United States
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:03 PM
List 10/10 to 10/24 Results $AKRO $ALE $ALG $ALGN $ALK 🔥 Cycle Trading Signal plugged into AI 🔥
0 · Reply
BioRich
BioRich Oct. 20 at 4:46 PM
$ALT Thanks again to @Wolly99 for his regular posting of misinformation. I feel compelled to research what you post because it usually leads to buying opportunities in $ALT competitors. Did you know that there's more than one AI Fibrosis Reader out there making waves? Look at HistoIndex. Looks like it's already used by $AKRO and $SGMT. Gave me a chance to look at SGMT also, and it looks like another "competitor" of $ALT's that has better results. For those pumping $ALT, I hope you realize it's a useless battle. $ALT is behind significant in the MASH/Fibrosis/Obesity races. $ALT is a "Has been", at best. Intriguing argument for what many THOUGHT Prmvi "could" do, only to be squashed when data showed what it CAN'T do. Bag holders unite! https://www.prnewswire.com/news-releases/histoindex-to-debut-fibrosight-plus-and-showcase-latest-scientific-findings-at-aasld-the-liver-meeting-2025-302584158.html
1 · Reply
DoomBot1
DoomBot1 Oct. 16 at 12:42 AM
$NVO wasting shareholders money buying trash companies like $OMER and $AKRO ? xD, what about cost cutting?, useless management. 45 eoy
2 · Reply
MStew_Swinger
MStew_Swinger Oct. 14 at 5:20 PM
$AKRO Patients win, payors win, investors win. That triple alignment is rare. When survival rises by 50 to 70 points on earlier detection and spend drops by double digits, the contract cycle shortens and renewal rates approach software like levels
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 14 at 10:36 AM
$AKRO Akero Therapeutics jumps 16.52% as new clinical data for efruxifermin shows major liver health gains in MASH patients. https://biotechhealthx.com/biotech-news/akero-therapeutics-akro-soars-16-52-after-liver-drug-breakthrough-shocks-wall-street/
0 · Reply
MilsLearning
MilsLearning Oct. 14 at 9:05 AM
$AKRO “L"ets "F" ry "S"horts 🔥🩳🔥🩳🖕🩳🖕🩳🔥🩳🖕🩳✅ Ever get bullied??? Trading stocks?? Me too!!! Amazing seeing shorts frying all over the market today 🔥❤️🔥❤️🔥❤️🔥 Get the bullies out of the schools The IPO Foreign Meme movement ***LFS***
0 · Reply
RobertPittman
RobertPittman Oct. 13 at 3:31 PM
$AKRO NXXT now screens on growth and scarcity. 229% YoY revenue growth in September, $58.6M YTD, 74% insider hold, and a float around 35M. That mix often precedes outsized moves when new buyers arrive.
0 · Reply
PickAlpha
PickAlpha Oct. 13 at 1:27 PM
pt 4/6: Novo Nordisk to acquire Akero Therapeutics for up to $5.20B: $54 cash per share (~$4.7B) + $6 CVR on U.S. approval by June 2031 $AKRO $NVO $LLY $XBI
0 · Reply
FE123
FE123 Oct. 13 at 10:59 AM
$AKRO 5.3 Billion Buyout! $MTSR 7.6 Billion Buyout! $VKTX over $11 Billion!
0 · Reply
MilsLearning
MilsLearning Oct. 13 at 7:39 AM
$AKRO "L"ets "F" "S"horts 🔥🖕🩳🖕🔥🖕🩳🖕🔥🩳🖕🔥🕖✅🔜 Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***
0 · Reply
Latest News on AKRO
My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 5 days ago

My Top 3 Pharma Stocks

BMY ETNB LLY MRK NVO PFE SPY


Akero Therapeutics Stock Soars on Novo Nordisk Deal.

Oct 9, 2025, 7:31 AM EDT - 16 days ago

Akero Therapeutics Stock Soars on Novo Nordisk Deal.

NVO


Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Oct 9, 2025, 6:39 AM EDT - 16 days ago

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

NVO


Novo Nordisk buys Akero Therapeutics in the US

Oct 9, 2025, 6:09 AM EDT - 16 days ago

Novo Nordisk buys Akero Therapeutics in the US

NVO


Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Apr 6, 2025, 1:47 PM EDT - 7 months ago

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock


BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:03 PM
List 10/10 to 10/24 Results $AKRO $ALE $ALG $ALGN $ALK 🔥 Cycle Trading Signal plugged into AI 🔥
0 · Reply
BioRich
BioRich Oct. 20 at 4:46 PM
$ALT Thanks again to @Wolly99 for his regular posting of misinformation. I feel compelled to research what you post because it usually leads to buying opportunities in $ALT competitors. Did you know that there's more than one AI Fibrosis Reader out there making waves? Look at HistoIndex. Looks like it's already used by $AKRO and $SGMT. Gave me a chance to look at SGMT also, and it looks like another "competitor" of $ALT's that has better results. For those pumping $ALT, I hope you realize it's a useless battle. $ALT is behind significant in the MASH/Fibrosis/Obesity races. $ALT is a "Has been", at best. Intriguing argument for what many THOUGHT Prmvi "could" do, only to be squashed when data showed what it CAN'T do. Bag holders unite! https://www.prnewswire.com/news-releases/histoindex-to-debut-fibrosight-plus-and-showcase-latest-scientific-findings-at-aasld-the-liver-meeting-2025-302584158.html
1 · Reply
DoomBot1
DoomBot1 Oct. 16 at 12:42 AM
$NVO wasting shareholders money buying trash companies like $OMER and $AKRO ? xD, what about cost cutting?, useless management. 45 eoy
2 · Reply
MStew_Swinger
MStew_Swinger Oct. 14 at 5:20 PM
$AKRO Patients win, payors win, investors win. That triple alignment is rare. When survival rises by 50 to 70 points on earlier detection and spend drops by double digits, the contract cycle shortens and renewal rates approach software like levels
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 14 at 10:36 AM
$AKRO Akero Therapeutics jumps 16.52% as new clinical data for efruxifermin shows major liver health gains in MASH patients. https://biotechhealthx.com/biotech-news/akero-therapeutics-akro-soars-16-52-after-liver-drug-breakthrough-shocks-wall-street/
0 · Reply
MilsLearning
MilsLearning Oct. 14 at 9:05 AM
$AKRO “L"ets "F" ry "S"horts 🔥🩳🔥🩳🖕🩳🖕🩳🔥🩳🖕🩳✅ Ever get bullied??? Trading stocks?? Me too!!! Amazing seeing shorts frying all over the market today 🔥❤️🔥❤️🔥❤️🔥 Get the bullies out of the schools The IPO Foreign Meme movement ***LFS***
0 · Reply
RobertPittman
RobertPittman Oct. 13 at 3:31 PM
$AKRO NXXT now screens on growth and scarcity. 229% YoY revenue growth in September, $58.6M YTD, 74% insider hold, and a float around 35M. That mix often precedes outsized moves when new buyers arrive.
0 · Reply
PickAlpha
PickAlpha Oct. 13 at 1:27 PM
pt 4/6: Novo Nordisk to acquire Akero Therapeutics for up to $5.20B: $54 cash per share (~$4.7B) + $6 CVR on U.S. approval by June 2031 $AKRO $NVO $LLY $XBI
0 · Reply
FE123
FE123 Oct. 13 at 10:59 AM
$AKRO 5.3 Billion Buyout! $MTSR 7.6 Billion Buyout! $VKTX over $11 Billion!
0 · Reply
MilsLearning
MilsLearning Oct. 13 at 7:39 AM
$AKRO "L"ets "F" "S"horts 🔥🖕🩳🖕🔥🖕🩳🖕🔥🩳🖕🔥🕖✅🔜 Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***
0 · Reply
swingingtech
swingingtech Oct. 10 at 8:22 PM
$DJIA $MP $TSLA $AKRO $DAL https://www.pivotandflowdaily.com/p/october-10th-market-overview-2fd4
0 · Reply
oaklynnzhang27
oaklynnzhang27 Oct. 10 at 7:13 PM
$AKRO NXXT needs volume confirmation. Seek 150 to 200 percent of 10 day average during the first 90 minutes. Combine with 2.10 reclaim and VWAP hold and 2.22 to 2.30 usually tags fast.
0 · Reply
Wolly99
Wolly99 Oct. 10 at 3:05 PM
$ALT I'm going to keep pounding home that no other company had good or stat sig interim phase 2 results with histoligic fibrosis scoring. Here is $AKRO phase 2, 36-week readout that was called "encouraging". Keep in mind this is an FGF21 - the powerful anti-fibrotic. No stat sig, 10% treatment effect. TBH: what ALT did was genius. Understand that phase 2 trials are not powered significantly for fibrosis response, so focus on MASH resolution, same as NVO and MDGL. Then move to p3 as fast as possible where you can have more power. But they're designing p3 right as the paradigm is shifting to NITs. They saved an unbelieveable amount of money not doing biopsy through week 48 on an endpoint that no one has hit.
2 · Reply
AKvf
AKvf Oct. 10 at 2:49 PM
Jyske Bank says $NVO ’s $4.7B acquisition of $AKRO, its largest R&D deal ever, strengthens its pipeline in MASH, a severe liver disease with no approved treatments. While the market initially reacted negatively due to uncertainty around MASH and higher near-term R&D costs, Jyske Bank calls the deal “overall positive.” Novo gains rights to Efruxifermin, seen as a potential first- and best-in-class treatment for advanced (F4) MASH, possibly used alone or with Wegovy, which already targets earlier MASH stages. With an estimated 250M people globally affected, the unmet need is huge. Rival pharma giants Roche and GSK have also made recent MASH-focused acquisitions, underscoring the field’s growing importance.
0 · Reply
StockMeister2
StockMeister2 Oct. 10 at 1:04 PM
$AKRO Akero Akero https://www.youtube.com/watch?v=DUT5rEU6pqM
0 · Reply
GreylockSec
GreylockSec Oct. 10 at 12:04 PM
$TPST ...Biotech is back! ...Liver disease Biotech, Akero Therapeutics $AKRO to be Acquired by Novo Nordisk for up to $5.2 Billion. $54 in cash with an extra $6 in CVR's. $TPST next in line 💥
5 · Reply
JarvisFlow
JarvisFlow Oct. 10 at 10:50 AM
HC Wainwright & Co. has adjusted their stance on Akero Therapeutics ( $AKRO ), setting the rating to Neutral with a target price of 54.
0 · Reply
bginvest
bginvest Oct. 10 at 10:32 AM
$AKRO $ALGS $IVA $MDGL $NVO the big institutional investors have a PT of 1000dkr on a Danish biotech company in the same sector that’s Zealand Pharma 📈🤔🤷‍♂️
0 · Reply
Quantumup
Quantumup Oct. 10 at 10:08 AM
Oppenheimer⬆️ $MDGL's PT to $590 from $500 and reiterated at an Outperform rating. $NVO $AKRO $IVA $ALGS Oppenheimer said: With Novo Nordisk announcing plans to acquire Akero Therapeutics, the importance of combinations moves to the forefront for MASH investors along three key dimensions: 1) combination approaches to treating MASH with orthogonal and complementary mechanisms; 2) combination of portfolios to address a broad range of MASH patients including F2-F3 and F4; and 3) combination of corporate entities developing and commercializing MASH therapeutics to optimize capabilities and outcomes. While some investors were apparently disappointed that MDGL was not acquired, we see favorable points of read-across: 1) Rezdiffra is already entrenched as a foundational therapy to be considered for any oral combination MASH regimens; and 2) MDGL has acquired a GLP-1 as SYH2086 has all the properties required for a daily oral combo.
0 · Reply
biostock
biostock Oct. 10 at 5:28 AM
AI summary of $SGMT 's FASN Inhibitor VS $AKRO $ETNB 's FGF21 Analogs in MASH. $QQQ $SPY Under the radar, under valued stock.
1 · Reply
biostock
biostock Oct. 9 at 10:40 PM
$SGMT Stocks needs to 10X from here to reach at half of recent valuation paid for $ETNB and $AKRO buyout. $QQQ $SPY Let that sink in.
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:12 PM
Keep a close watch on CMCT! $AKRO $BTBT $DKNG $LYFT
1 · Reply